Chemotherapy Combined With Camrelizumab and Apatinib in First-line Treatment of ES-SCLC

NCT05001412 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

36

Enrollment

OTHER

Sponsor class

Conditions

Extensive Stage Small Cell Lung Cancer

Interventions

DRUG: Camrelizumab; apatinib; carboplatin; etoposide

Sponsor

Zhou Chengzhi

Collaborators

[object Object]